Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction

Advanced Drug Delivery Reviews

Volumn 55, Issue 10, 2003, Pages 1337-1345

  Moreadith, Randall W ^a   Collen, Désiré ^a  

^a ThromboGenics NV   (Belgium)

Author keywords

Acute myocardial infarction; Coronary recanalization; Fibrin selective therapy; Intracranial hemorrhage; Recombinant staphylokinase; Thrombolysis

Indexed keywords

COST EFFECTIVENESS; DISEASES; MOLECULAR WEIGHT; MOLECULES; PATIENT TREATMENT; POLYETHYLENE GLYCOLS;

CORONARY ARTERIES; PLASMINOGENS;

DRUG INFUSION;

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENZYME VARIANT; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MUTANT PROTEIN; PROTEIN SAKSTAR; PROTEIN SY155; PROTEIN SY161 P10; PROTEIN SY161 P20; PROTEIN SY161 P5; RECOMBINANT ENZYME; RETEPLASE; SARUPLASE; STAPHYLOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROSS LINKING; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0345283158     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00113-3     Document Type: Article

References (18)

1. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation. 93:1996;857-865.
2. A comparison of reteplase with alteplase for acute myocardial infarction. New Engl. J. Med. 337:1997;1118-1123.
3. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the assent-3 randomised trial in acute myocardial infarction. Lancet. 358:2001;605-613.
4. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat. Med. 4:1998;279-284.
5. Collen D., Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 87:1993;1850-1853.
6. Vanderschueren S., Barrios L., Kerdsinchai P., et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction: the STAR Trial Group. Circulation. 92:1995;2044-2049.
7. Vanderschueren S., Dens J., Kerdsinchai P., et al. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am. Heart J. 134:1997;213-219.
8. Abuchowski A., McCoy J.R., Palczuk N.C., et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252:1977;3582-3586.
9. Inada Y., Furukawa M., Sasaki H., et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 13:1995;86-91.
10. Vanwetswinkel S., Plaisance S., Zhang Z., et al. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood. 95:2000;936-942.
11. Laroche Y., Heymans S., Capaert S., et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood. 96:2000;1425-1432.
12. Schott B., Hartman M., Guhrs K.H., et al. High yield production and purification of recombinant staphylokinas for thrombolytic therapy. Biotechnology. 12:1994;185-189.
13. Tartof K.D., Hobbs C.A. Improved media for growing plasmid and cosmid clones. Bethesda Res. Lab Focus. 9:1987;12.
14. Collen D., Sinnaeve P., Demarsin E., et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation. 102:2000;1766-1772.
15. Collen D., Moreau H., Stockx L., et al. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation. 94:1996;207-216.
16. Armstrong P.W., Burton J.R., Palisaitis D., et al. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). Am. Heart J. 139:2000;820-823.
17. Armstrong P.W., Burton J., Pakola S., Molhoek P.G., Betriu A., Tendera M., Bode C., Adgey A.A.J., Bar F., Vahanian A., Van de Werf F. Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS II). Presented at the George Washington Symposium at the American College of Cardiology meeting, March :2002.
18. C. Johnson, M. Royal, R. Moreadith, F. Bedu-Addo, S. Advant, M. Wan, G. Conn, Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse phase chromatography. J. Biomed. Chromatogr. submitted for publication.